BC cell model experiments have proved that the inhibitors have strong anti-tumor effects, and also confirmed that they can inhibit the PI3K pathway, but unfortunately they have the disadvantages of poor solubility, instability and high toxicity, so they are limited to pre-clinical studies (Fruman et al., 2017; Liu et al., 2017). Here, PIK3CA is linked to breast cancer.